In accordance with the Generic Drug User Fee Amendments (GDUFA), FDA consults with industry and the public to create an annual list of regulatory science initiatives on generic drugs. These priorities are discussed and developed in public meetings and workshops, resulting in several awarded projects
Similar Posts
Maypharm – 718717 – 11/03/2025
Unapproved New Drugs/Misbranded BotoxHow to Participate in Emerging Technology Program (ETP)
CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.CDER Small Business & Industry Assistance (SBIA)
A Comprehensive Resource for Information on Human Drug Development in RegulationGenetic Metabolic Diseases Advisory Committee (GeMDAC) Charter
The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.Medication Health Fraud for Specific Diseases and Conditions
FDA has identified condition-specific medication health fraud scams that can pose significant risks to consumers.ByHeart Inc. dba BlendHouse Allerton. Allerton, IA. EIR issued 01/30/2024
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 01/30/2024
Short Title (70 char) ByHeart Inc. dba BlendHouse Allerton. Allerton, IA. EIR issued 01/30/2024
FEI Number 1921383
Firm Name ByHeart Inc. dba BlendHouse Allerton
Record Type EIR
State IA
Establishment